Retrospective correlation of different therapeutic strategies and outcomes in intensive care patients with reactivation of Herpesviridae

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038751

Enrollment

400

Registered

2025-12-22

Start date

2025-04-16

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B00

Interventions

Group 1: Retrospective analysis of all patients aged over 18 who were treated for SARS-CoV-2 infection in the anesthesiology intensive care unit of University Hospital Essen, Germany, between March 20

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria were admission to the ICU and a confirmed positive test for SARS-CoV-2.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The primary endpoint was defined as ICU mortality . Mortality was defined as death from any cause occurring during the initial ICU admission. Secondary endpoints included the crude incidence of HSV, CMV, candida and aspergillus co-presence, the use of antiviral and antifungal therapy, organ failure, need for mechanical ventilation and need for venovenous extracorporal membrane oxygenation (vvECMO) support.	—

Measure

Time frame

The primary endpoint was defined as ICU mortality . Mortality was defined as death from any cause occurring during the initial ICU admission. Secondary endpoints included the crude incidence of HSV, CMV, candida and aspergillus co-presence, the use of antiviral and antifungal therapy, organ failure, need for mechanical ventilation and need for venovenous extracorporal membrane oxygenation (vvECMO) support.

—

Secondary

Measure	Time frame
Secondary endpoints included the crude incidence of HSV, CMV, candida and aspergillus co-presence, the use of antiviral and antifungal therapy, organ failure, need for mechanical ventilation and need for venovenous extracorporal membrane oxygenation (vvECMO) support.	—

Countries

Germany

Contacts

Public ContactSimon Dubler

Universitätsklinikum Essen

simon.dubler@uk-essen.de02017231401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026